These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17002483)

  • 21. Economic Decision Model Suggests Total Shoulder Arthroplasty is Superior to Hemiarthroplasty in Young Patients with End-stage Shoulder Arthritis.
    Bhat SB; Lazarus M; Getz C; Williams GR; Namdari S
    Clin Orthop Relat Res; 2016 Nov; 474(11):2482-2492. PubMed ID: 27457626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
    Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.
    Hiligsmann M; Ethgen O; Bruyère O; Richy F; Gathon HJ; Reginster JY
    Value Health; 2009; 12(5):687-96. PubMed ID: 19508659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.
    Bansback N; Ara R; Karnon J; Anis A
    Pharmacoeconomics; 2008; 26(5):395-408. PubMed ID: 18429656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
    de Jong PH; Hazes JM; Buisman LR; Barendregt PJ; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
    Rheumatology (Oxford); 2016 Dec; 55(12):2138-2147. PubMed ID: 27581208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
    Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.
    Diamantopoulos A; Benucci M; Capri S; Berger W; Wintfeld N; Giuliani G; Ricciardi W
    J Med Econ; 2012; 15(3):576-85. PubMed ID: 22313326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
    Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
    Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.